BioSpace News Archive

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its support for the Biden Administration’s plan to expand COVID-19 testing in schools, underserved communities, rural areas and other settings that have been gravely impacted by the pandemic.

Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, today announced the pricing of its upsized initial public offering of 16,000,000 shares of common stock at a price to the public of $20.00 per share.

CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a webinar to continue educating the Duchenne community about the COVID-19 vaccines.

Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $5.75 per share

Health Canada confirms that the benefits of the AstraZeneca COVID-19 vaccine in protecting Canadians from COVID-19 continue to outweigh the risks, and encourages Canadians to get immunized with any of the COVID-19 vaccines that are authorized in Canada.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $17.00 per share.